Private company

Forma Therapeutics Holdings, Inc.

American biological products company, incorporated in Delaware1

In its 2022 annual report the company says: “We are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our drug discovery expertise has generated a pipeline of product candidates focused on indications with significant unmet patient need.”44 It is headquartered in Watertown, Massachusetts.1

Last updated Oct 20, 2026.

Overview

  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersWatertown, Massachusetts1
  • Incorporated inDE2
  • Business address300 North Beacon Street, Suite 501, Watertown, Ma 024722
  • Filer categoryLarge accelerated filer2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-34.7%Return on equity3
-$154.0MFree cash flow3

Financial statements

Revenue43$0 in 2021
0$50.0M$100.0M$150.0M2019: $100.6M$100.6M20192020: $0$020202021: $0$02021
Operating income43-$174.0M in 2021+330% since 2019
-$200.0M-$150.0M-$100.0M-$50.0M02019: -$40.5M-$40.5M20192020: -$124.2M-$124.2M2020+207%2021: -$174.0M-$174.0M2021+40%
Net income43-$173.0M in 2021+397% since 2019
-$200.0M-$150.0M-$100.0M-$50.0M02019: -$34.8M-$34.8M20192020: -$70.4M-$70.4M2020+102%2021: -$173.0M-$173.0M2021+146%
Fiscal year2018201920202021
Revenue$100.6M4$03$03
Research and development$111.3M4$93.4M3$125.7M3
Operating expenses$174.0M3
Operating income-$40.5M4-$124.2M3-$174.0M3
Income before tax-$172.8M3
Income tax-$1.8M4$29.7M3$154.0K3
Net income-$34.8M4-$70.4M3-$173.0M3
Earnings per share-$20.704-$3.224
Earnings per share (diluted)-$21.084-$3.224

Compare Forma Therapeutics Holdings, Inc. with another company

Corporate structure

Forma Therapeutics Holdings, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Forma Therapeutics Holdings, Inc.

  • Deep Track Capital, LP Filed SC 13G/A on Forma Therapeutics Holdings, Inc., latest Feb 14, 2023 (2 filings since Jun 3, 2022)
  • RA CAPITAL MANAGEMENT, L.P. Filed SC 13D/A on Forma Therapeutics Holdings, Inc., latest Oct 14, 2022 (3 filings since Oct 28, 2021)
  • FMR LLC Filed SC 13G/A on Forma Therapeutics Holdings, Inc., latest May 10, 2022 (2 filings since Feb 9, 2022)
  • Cormorant Asset Management, LP Filed SC 13G/A on Forma Therapeutics Holdings, Inc., latest Feb 14, 2022
  • Novartis Bioventures Ltd Filed SC 13G/A on Forma Therapeutics Holdings, Inc., latest Feb 11, 2022
  • VANGUARD GROUP INC Filed SC 13G on Forma Therapeutics Holdings, Inc., latest Feb 10, 2022
  • Forma Therapeutics Holdings, Inc. Watertown, Massachusetts

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Forma Therapeutics Holdings, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Leasehold improvements$5.8M3 Dec 31, 2021$03 Dec 31, 2020
Property and equipment, before depreciation$18.7M3 Dec 31, 2021$13.1M3 Dec 31, 2020+43.1%
Accumulated depreciation$4.8M3 Dec 31, 2021$11.5M3 Dec 31, 2020−58.7%
Property and equipment, net$13.9M3 Dec 31, 2021$1.5M3 Dec 31, 2020+816.2%
Operating-lease assets (leased space)$22.1M3 Dec 31, 2021$7.5M3 Jan 1, 2021+194.3%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$77.4M3 Dec 31, 2021$282.7M3 Dec 31, 2020−72.6%
Marketable securities, current$386.8M3 Dec 31, 2021$350.4M3 Dec 31, 2020+10.4%
Marketable securities, non-current$26.0M3 Dec 31, 2021$12.5M3 Dec 31, 2020+107.8%
Debt securities held to maturity$412.9M3 Dec 31, 2021$362.9M3 Dec 31, 2020+13.8%

Leadership

Who has led Forma Therapeutics Holdings, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Frank D. Lee2020–2022

President

  1. Frank D. Lee2020–2022

Chief financial officer

  1. Todd Shegog2020–2022
2025
Board members and other officers (18)

Former names

  • Forma Therapeutics Holdings, Inc.,Apr 8, 2020 to Jul 30, 20202
  • Forma Therapeutics Holdings LLCJan 17, 2012 to Sep 6, 20122

Timeline

  1. Oct 14, 20228-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer26
  2. Sep 1, 20228-K Entered a material agreement; Other events27
  3. Aug 5, 20228-K Results of operations28
  4. Jul 25, 20228-K Executive or director change29
  5. Jun 9, 20228-K Shareholder vote30
  6. May 26, 20228-K Regulation FD disclosure; Other events31
  7. May 6, 20228-K Results of operations32
  8. Mar 1, 20228-K Results of operations; Other events33
  9. Jan 13, 20228-K Executive or director change34
  10. Dec 16, 20218-K Regulation FD disclosure; Other events35
  11. Dec 13, 20218-K Regulation FD disclosure; Other events36
  12. Nov 12, 20218-K Results of operations37
  13. Jun 18, 2020New chief executive Frank D. Lee becomes CEO7

Calendar

When it reported results

  1. Aug 5, 2022Reported quarterly or annual results28
  2. May 6, 2022Reported quarterly or annual results32
  3. Mar 1, 2022Reported quarterly or annual results33
  4. Nov 12, 2021Reported quarterly or annual results37

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

90 filings to the SEC since October 2021: 1 annual reports, 3 quarterly reports, 13 major events, 42 insider forms, 10 large holders, 21 other. The latest 20:

  1. Feb 14, 2023SC 13G/A EDGAR
  2. Oct 24, 202215-12G EDGAR
  3. Oct 17, 2022EFFECT EDGAR
  4. Oct 14, 2022S-8 POS EDGAR
  5. Oct 14, 2022POS AM EDGAR
  6. Oct 14, 2022S-8 POS EDGAR
  7. Oct 14, 2022S-8 POS EDGAR
  8. Oct 14, 2022S-8 POS EDGAR
  9. Oct 14, 2022SC 14D9/A EDGAR
  10. Oct 14, 20228-K EDGAR
  11. Oct 14, 2022SC 13D/A EDGAR
  12. Oct 14, 20224 OWNERSHIP DOCUMENT EDGAR
  13. Oct 14, 20224 FORM 4 SUBMISSION EDGAR
  14. Oct 14, 20224 FORM 4 SUBMISSION EDGAR
  15. Oct 14, 20224 FORM 4 SUBMISSION EDGAR
  16. Oct 14, 20224 FORM 4 SUBMISSION EDGAR
  17. Oct 14, 20224 FORM 4 SUBMISSION EDGAR
  18. Oct 14, 20224 FORM 4 SUBMISSION EDGAR
  19. Oct 14, 20224 FORM 4 SUBMISSION EDGAR
  20. Oct 14, 20224 FORM 4 SUBMISSION EDGAR

The 90 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

7 open-market trades by officers, directors and large owners since October 2021: 0 buys and 7 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Feb 23, 2022COOK DAVID NSVP, Chief Scientific OfficerSale3,531$9.78$34.5KForm 4
Feb 23, 2022Lee Frank D.President and CEOSale17,981$9.78$175.9KForm 4
Feb 23, 2022Kelly Patrick F.SVP, Chief Medical OfficerSale5,245$9.78$51.3KForm 4
Feb 23, 2022Shegog ToddSVP, Chief Financial OfficerSale5,687$9.78$55.6KForm 4
Feb 23, 2022Lesser Brian AndrewSVP, Commercial OfficerSale3,837$9.78$37.5KForm 4
Feb 23, 2022Wadlinger Mary E.See RemarksSale4,684$9.78$45.8KForm 4
Feb 23, 2022Potts JeannetteSee RemarksSale4,672$9.78$45.7KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Forma Therapeutics Holdings, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARForma Therapeutics Holdings, Inc.1
  • CIK0001538927
  • Employer ID (EIN)37-16571291
  • Filer statusLarge accelerated filer1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • Business address300 North Beacon Street, Suite 501, Watertown, MA 024721
  • Phone617-679-19701
  • Shares outstanding47,852,557 as of Aug 1, 20226
  • Public float$1.2B as of Jun 30, 20213
  • On EDGAR sinceJan 17, 20121
  • Filings216 in all: 4 (79), 8-K (26), 3 (22), SC 13G/A (9), 10-Q (7), SC 13G (7), CORRESP (6), EFFECT (4)1
    All 38 form types

    S-8 (4), S-8 POS (4), UPLOAD (4), SC 13D/A (3), SC 14D9/A (3), SC TO-T/A (3), 10-K (2), 424B4 (2), D (2), DEF 14A (2), DEFA14A (2), DRS (2), DRS/A (2), POS AM (2), S-1 (2), S-1MEF (2), SC14D9C (2), 15-12G (1), 25-NSE (1), 3/A (1), 8-A12B (1), CERT (1), DRSLTR (1), POSASR (1), S-1/A (1), S-3ASR (1), SC 13D (1), SC 14D9 (1), SC TO-C (1), SC TO-T (1)

  • Latest filingsAnnual report (10-K) Mar 1, 2022
    Quarterly report (10-Q) Aug 5, 2022
    Proxy statement (DEF 14A) Apr 27, 2022
    Latest 8-K (8-K) Oct 14, 2022

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44